
Jill Feldman/henryford.com
Apr 28, 2025, 23:45
Jill Feldman: Dr Shokat at AACR25 on How Progress in Studying KRAS Led to Developing Drugs to Target It
Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:
“Dr Shokat talk at opening plenary at AACR25 on how progress in studying KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never… The impossible can be possible.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 17:40
Apr 28, 2025, 17:31